ProtaGene is a world-leading analytic CRO partner for the biopharmaceutical and cell and gene therapies industries. From research through commercial product release and testing, we provide the most advanced, integrated, and complete analytical capabilities and packages. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our best-in-class data packages and test reporting provide scientific, technical and regulatory support to advance, de-risk and accelerate all stages of biopharmaceutical development. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.
Jul 08, 2022
Posted by ProtaGene